ABL Diagnostics (XPAR:ABLD) ROCE %: 8.99% (As of Dec. 2025)


XPAR:ABLD ABL Diagnostics XPAR:ABLD
51 GF Score
Price €2.66
GF Value €7.71
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics ROCE %?

ABL Diagnostics XPAR:ABLD +0.76% 51 ROCE % is 8.99% as of Dec. 2025. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ABL Diagnostics's annualized ROCE % for the quarter that ended in Dec. 2025 was 8.99%.

ABL Diagnostics  (XPAR:ABLD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ABL Diagnostics ROCE % Related Terms

ABL Diagnostics ROCE % Historical Data

* Premium members only.

The historical data trend for ABL Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABL Diagnostics ROCE % Chart

ABL Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.14 1.49 -6.28 -4.17 4.22

ABL Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.52 -5.07 -3.94 0.06 8.99
XPAR:ABLD
51GF Score
ABL Diagnostics XPAR:ABLD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABL Diagnostics ROCE % Calculation

ABL Diagnostics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=0.403/( ( (11.81 - 1.759) + (12.955 - 3.915) )/ 2 )
=0.403/( (10.051+9.04)/ 2 )
=0.403/9.5455
=4.22 %

ABL Diagnostics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=0.8/( ( (11.101 - 2.342) + (12.955 - 3.915) )/ 2 )
=0.8/( ( 8.759 + 9.04 )/ 2 )
=0.8/8.8995
=8.99 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.99% mean?
ABL Diagnostics (XPAR:ABLD) has a ROCE % of 8.99% as of Dec. 2025.
Is ABL Diagnostics' ROCE % too high?
ABL Diagnostics' current ROCE % is 8.99%. The Healthcare Providers & Services industry median ROCE % is 6.41. ABL Diagnostics' value of 8.99% is 40.2% above this industry median. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' ROCE % compare to VEEV and BTSG?
ABL Diagnostics' ROCE % of 8.99% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. ABL Diagnostics' value of 8.99% is 40.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 643 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current ROCE % of 8.99% is 40.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current ROCE % is 8.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current ROCE % is 8.99% and 40.2% above the Healthcare Providers & Services industry median of 6.41. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current ROCE % is 8.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • ROCE %: 8.99%
  • GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs
  • Industry Position: 40.2% above the Healthcare Providers & Services median

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score

Get the complete analysis for XPAR:ABLD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€7.71
GF Value